Shanghai-based Anew Labs announced about $290M in inaugural external financing on September 16, 2026, from HSG, IDG Capital, Hillhouse, and 5Y Capital. Spun out of ByteDance, which retains a 56% stake, the company applies AI to drug discovery.
ByteDance-spun Anew Labs raises $290M for AI-driven drug discovery
Healthtech and biotech founders should watch AI-first drug discovery entrants as potential partners or competitors; the scale of this raise shows capital is flowing to AI applied in regulated science.
Source: Tech Startups
More that helps you.
Factory raises $200M at $5B valuation for its AI coding agents
AI software-engineering startup Factory raised $200 million at a $5 billion valuation on Sept 16, 2026, roughly tripling the $1.5B valuation from its $150M Series C five months ear…
Arcee AI hits $1B+ valuation with $150M Series B for open-weight models
Arcee AI announced a $150M+ Series B on Sept 16, 2026 valuing it above $1 billion, led by Vista Equity, Cambium and Emergence with Hitachi, Wipro and M12. It built its Trinity mode…
Paris-based Arlequin AI raises EUR 28M for LLM-alternative topological neural networks
Arlequin AI closed a EUR 28 million Series A on September 10, 2026, co-led by redalpine and OTB Ventures with Bpifrance's Defence Innovation Fund and Xavier Niel joining. Its topol…
Australia's Metacognition AI raises $10M for an AI operating-system layer
Australian lab Metacognition AI announced a roughly $10 million round on September 10, 2026, led by CSIRO-backed VC Main Sequence. It is building an operating-system layer that sit…
Get briefs like this tuned to you.
In the app, Founder Briefs are personalized to your country, industry and stage, and you can save the ones that matter.
See plans →